Speaking of distribution, how can DECN, or any company, have ACCOUNTS RECEIVABLE ($1,045,166) EQUAL TO ALMOST HALF OF THE ANNUAL REVENUES ($2,379,234)?
Can you say, "Berman is ignoring a potentially huge BAD DEBT write-off!"? This BS brings new meaning to the claimed "slow pay"!
DECN's annual report approaches being misleading and definitely communicates DECN is a financial mess! IMO, the diabetes testing business is ridiculous, starting with a nearly 80% Cost of Goods! Setting the newly announced COVID-19 testing initiative aside, there is no way even a .02 share price can come close to being rationalized! If the annual report would have been audited, DECN would have gotten hammered for carrying average receivables of nearly 180 days to pay, the bloated valuations for the IP and Patents, and no write-downs of the custom manufacturing equipment, just to name three significant concerns. Suffice it to say, IMO, DECN's financial condition is certainly worse than what is being conveyed in the 2019 Annual Financial Report.